Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Maravai LifeSciences Q1 revenue rises 40.5% to $65.8 million; full-year guidance raised

Positive Impact 4 of 5 earnings Written later

Maravai LifeSciences reported first-quarter 2026 revenue of $65.8 million, up 40.5% from a year earlier, and a net loss of $6.4 million, compared with a $52.9 million loss in the prior-year quarter. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, though the TriLink revenue jump includes $14.3 million of high-volume COVID-19 vaccine CleanCap orders.

Key points

  • Q1 2026 revenue was $65.8 million, up from $46.9 million; TriLink revenue rose 65.1% and Cygnus rose 1.4%
  • Net loss narrowed to $(6.4) million from $(52.9) million; Adjusted EBITDA was $20.3 million versus $(10.5) million
  • Full-year 2026 revenue guidance raised to $205.0 million to $215.0 million from $200.0 million to $210.0 million
  • Full-year 2026 Adjusted EBITDA guidance raised to $30.0 million to $32.0 million from $18.0 million to $20.0 million; free cash flow was $4.2 million

The filing

CompanyMARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
Form8-K, current report
Filed with the SECMay 7, 2026, 4:05 PM ET
Accession number0001823239-26-000022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.